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Background: Functional tricuspid regurgitation (FTR) is frequent in patients with mitral valve disease. Untreated
tricuspid regurgitation (TR) may cause poor clinical outcomes. The surgical factors involved in annuloplasty for
FTR remain controversial. Our objective was to compare effectiveness of different tricuspid annuloplasty (TVP),
and reveal the risk factors of recurrence.
Methods: We analyzed the clinical details of 399 consecutive patients who underwent mitral surgery with
concomitant TVP, from 2006 to 2011, in two Chinese single-centers. Three methods were used for TVP: De
Vega surgery was completed in 242 patients; annuloplasty using a ﬂexible band was completed in 98 patients;
and surgery with a rigid ring was performed in 59 patients.
Results: The operative mortality rate was 2.3%. After surgery, the TR grade of all patients decreased signiﬁcantly.
At three years postoperatively, 13.7% of patientswere diagnosedwith recurrent FTR. At the three year time point,
severe TR in theDe Vega groupwas 18%,whichwas higher than those in the ﬂexible (8.4%) and rigid planner ring
groups (5.2%). During follow-up, the recurrent rates in the rigid group were signiﬁcantly lower than in the
ﬂexible group. Multivariate analysis revealed that pre-operative atrial ﬁbrillation, severe TR, large left atrial,
ejection fraction (EF) b 40%, De Vega annuloplasty, and postoperative permanent pacemaker installation were
independent risk factors for severe recurrent TR.
Conclusions: Rigid ring annuloplasty efﬁcaciously improved post-operative tricuspid valve function in patients
with FTR. Atrial ﬁbrillation, a large left atrium, low EF and postoperative permanent pacemaker installation
were independent risk factors for severe recurrent TR.© 2014 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Background
Tricuspid regurgitation (TR) is always present in patientswithmitral
valve (MV) disease, and over one-third of the patients with mitral
stenosis have at least moderate TR [1]. Patients with pre-operative se-
vere TR have severe MV disease, higher pulmonary vascular resistance,
and poorer outcomes. The functional label referring to TR, which is sec-
ondary to either left-sided heart disease (LHD) or pulmonary hyperten-
sion, could be possibly a misnomer [2]. If untreated at the time of MV
surgery, TR may progress, negatively impacting functional class, and
survival [3]. Patients with severe TR after MV surgery and who are
undergoing isolated tricuspid valve (TV) surgery, usually have high op-
erativemortality, and no signiﬁcant improvement in functional capacityhoracic Surgery, Changzheng
el./fax: +86 21 81885710.
en access article under the CC BY-NC[4,5]. On the contrary, many investigators have reported that even if
there was an absence of any organic pathology, TR would not reliably
resolve after the correction of the primary disorder [6–8].
Due to the common belief that TRwill resolve itself once the primary
LHD has been treated, cardiac surgeons have placed more attention on
intra-operative concomitant TR treatment. In the United States,
the total number of TV procedures more than doubled over the last
10-year period [9]. Although corrective surgery of severe functional TR
(FTR) showed trends toward improved survival, either signiﬁcant resid-
ual or recurrent TR has been reported in 15% to 40% of patients after
different TV surgery [10–12]. Tricuspid valve replacement, which allows
adequate surface area of co-aptation impossible, is associated with
higher mortality [13,14]. Several studies have shown better long-term
freedom from recurrent TV regurgitation and repeat operation in
those who underwent TV repair [15–20]; however, data regarding the
outcome of such an approach and the optimal surgical technique for
TV repair is lacking [6,21].-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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ﬁve years with Chinese patients in our institution to advance the under-
standing of the effectiveness, the durability of different TV annuloplasty
methods, and the risk factors involved with the surgical outcome.2. Methods
We retrospectively analyzed the clinical reports of 399 consecutive
patients (188 males, 211 females; age 46.7 years; range: 33–75 years)
who underwentmitral surgerywith concomitant tricuspid annuloplasty,
from January 2006 to June 2011, in two Chinese single-centers
(Changzheng Hospital and Changhai Hospital). Our exclusion criteria
included those with: an organic disease of the TV, either congenital
or infective tricuspid diseases, and either single or traumatic TR. Our
institutional ethics committee approved the present study and all
patients were given a written informed consent.
Each of the patients underwent pre-operative transthoracic echocar-
diography (TTE) within onemonth prior to surgery. The severity of FTR
was evaluated using an apical four-chamber view, and graded from 0 to
4+ (0: none, 1+: mild, 2+: moderate, 3+: moderate-to-severe, 4+:
severe).
All patients also underwent mitral surgery with cardiopulmonary
bypass (CPB) established between both the venae cavae and the ascend-
ing aorta. Mild systemic hypothermia was reported in all cases. The
myocardial protection used was identical for all patients, and consisted
of an anterograde cold blood crystalloid cardioplegia with topical ice
slush. We ﬁrst corrected the mitral valve disease, and then proceeded,
after aorta de-clamping, to perform a TV annuloplasty under the beating
heart. There were three procedures used to apply the tricuspid
annuloplasty: (1) De Vega group (DVGroup): 242 patients under either
traditional or modiﬁed De Vega surgery; (2) ﬂexible band group
(Flexible Group): annuloplasty with either the Duran ring (Medtronic)
or Cosgrove band (Cosgrove–Edwards annuloplasty system; Edwards
Lifesciences) in 98 patients; (3) and the rigid planner ring group
(Rigid Group): annuloplasty with MC3 ring (Edwards Lifesciences) in
59 patients. The type of tricuspid annuloplasty depended on a prefer-
ence of the surgeon. The diameter of the annuloplasty was measured
from the anteroseptal commissure to the antero-posterior commissure
using a sterile supple ruler [22]. And the surgeon would choose theTable 1
Preoperative clinical details of 399 patients with functional tricuspid regurgitation.
Variable De Vega group (n = 242, %)
Age 46.2 ± 15.4
Gender
Males 114 (47.1)
Females 128 (52.9)
NYHA⁎
Class II 90 (37.2)
Class III 92 (38.0)
Class IV 60 (24.8)
Atrial ﬁbrillation 109 (45.0)
Echocardiographic variables
Mitral stenosis 39 (16.1)
Mitral incompetence 88 (36.4)
Mitral mix lesions 115 (47.5)
mPAP⁎ 34.4 ± 12.3
mRVSP⁎ 43.9 ± 11.0
LVEF⁎ 55.1 ± 5.9
TR⁎ grade
1+ 3 (1.2)
2+ 67 (27.7)
3+ 89 (36.8)
4+ 83 (34.3)
The results of qualitative variables are expressed in absolute values (percentages) and the resu
⁎ NYHA = New York Heart Association; mPAP = mean pulmonary arterial pressure;
fraction; TR = tricuspid regurgitation.size of ring exactly according to the tricuspid diameter. We also
performed a direct injection test, and utilized transesophageal echocar-
diography for intra-operative evaluation of TV function. Seven days
after the valve repair, and at discharge, the temporal trend of the TR
grades was assessed by TTE.
Individual patient contact after discharge was performed during
either the outpatient process (69%), or with questionnaires (27%). Pa-
tients who did not respond were contacted by telephone (4%), and if
no further information about the patients was available, we contacted
their family physicians. The echocardiography data was evaluated
based on TR grade and images were obtained at three months, six
months, one year, and three years, postoperatively. The mean follow-
up time was 3.3 years (range, 6 months–5.5 years). Seven patients
were lost during follow-up. A total of 1467 TTE copies in 383 (96%)
patients were analyzed during the follow-up.
2.1. Statistical analyses
Results are expressed as either a number (percentages), mean
(standard deviation), or as a median (range) when the distribution of
variables was not normal. Continuous variables were compared using
either the Student t test or theMann–Whitney test and categorical out-
comes by either χ2 or Fisher's exact test. Univariate and multivariate
Cox proportional hazard models were used to examine the risk factors
for recurrent or persistent signiﬁcant TR. Variables with a p
value b 0.20 in univariate analyses were used for the multivariate
models. Multivariate analyses involved a backward elimination tech-
nique and only variables with a p value b 0.10 were included in the
ﬁnal model. All reported p values are two-sided and a p value b 0.05
was considered statistically signiﬁcant. Analyses were performed
using the SPSS version 13.0 (SPSS Inc, Chicago, IL).
3. Results
3.1. Baseline proﬁles
The etiology of the mitral lesion was rheumatic heart disease in 251
(62.9%), regressive in 108 (27.1%), and infective endocarditis in 40 pa-
tients (10.0%). When classiﬁed by using the pre-operative New YorkFlexible band group (n = 98, %) Rigid ring group (n = 59, %)
46.1 ± 14.7 47.7 ± 16.3
46 (46.9) 28 (47.5)
52 (53.1) 31 (52.5)
35 (35.7) 20 (33.9)
38 (38.8) 23 (40.0)
25 (25.5) 16 (27.1)
46 (46.9) 29 (49.2)
15 (15.3) 10 (16.9)
37 (37.8) 23 (40.0)
46 (46.9) 26 (44.1)
35.7 ± 14.6 37.1 ± 16.1
45.7 ± 12.9 45.1 ± 19.0
53.4 ± 4.1 56.2 ± 5.9
3 (3.0) 2 (3.4)
27 (27.6) 16 (27.1)
35 (35.7) 21 (35.6)
33 (33.7) 20 (33.9)
lts of continuous variables are expressed as mean (SD).
mRVSP = mean right ventricular systolic pressure; LVEF = left ventricular ejection
Table 2
Intraoperative and postoperative information of 399 patients undergoing concomitant tricuspid annuloplasty.
Variable De Vega group (n = 242, %) Flexible band group (n = 98, %) Rigid ring group (n = 59, %)
Intraoperative outcome
Mitral surgery
Mitral replacement 189 (78.1) 72 (73.5) 45 (76.3)
Mitral repair 50 (20.1) 25 (25.5) 13 (22.0)
Size of TV⁎ prosthetic ring
26 / 4 (4.1) 6 (10.2)
28 / 60 (61.2) 39 (66.1)
30 / 32 (32.3) 14 (23.7)
32 / 2 (2.0) 0 (0.00)
Concomitant surgery
CABG⁎ 3 (1.2) 1 (1.0) 1 (1.7)
CPB⁎ duration, minutes 75.0 ± 10.0 80.2 ± 10.7 81.4 ± 9.1
Aorta clamping time, minutes 42.1 ± 9.3 40.9 ± 6.5 39.2 ± 7.3
Mechanical ventilation time, hours 9.1 ± 1.1 8.3 ± 1.6 8.6 ± 1.5
ICU⁎ duration, days 2.4 ± 0.2 2.5 ± 0.4 2.4 ± 0.3
Hospital stay, days 16.1 ± 1.1 15.5 ± 1.4 15.0 ± 1.1
Postoperative outcome
Early death 5 (2.1) 2 (2.1) 2 (3.4)
Low output syndrome 2 0 0
MODS⁎ 2 1 2
Serve infection 1 1 0
Installation of permanent pacemaker 8 (3.3) 3 (3.1) 1 (1.7)
Reoperation due to TR⁎ in 5 years 5 2 0
Suture avulsion 4 1 /
Pacing wires 1 1 /
The results of qualitative variables are expressed in absolute values (percentages) and the results of continuous variables are expressed as mean (SD).
⁎ TV = tricuspid valve; CABG = coronary artery bypass graft; CPB = cardiopulmonary bypass; ICU = intensive care unit; MODS = multiple organ dysfunction syndrome;
TR = tricuspid regurgitation.
17Y. Lin et al. / IJC Heart & Vasculature 5 (2014) 15–19Heart Association (NYHA) functional class, 255 patients (64%) were in
both classes III and IV. By TTE, a TR grade of 1+ or 2+ was in 119 pa-
tients (29.8%) and a grade of 3+ or 4+ was in 280 patients (71.2%);
mean right ventricular systolic pressure (mRVSP) was 44.2 ±
16.1 mm Hg and mean pulmonary arterial pressure (mPAP) was
35.2 ± 12.1 mm Hg. There were no signiﬁcant differences in the pre-
operative clinical details of patients in the three groups, such as age,
gender, NYHA class, TTE results, or the percent of TR 3+ or 4+ grades
(Table 1).3.2. Clinical outcomes
During surgery, there were no signiﬁcant differences found within
groups regarding CPB, aorta clamping time, and concomitant surgery.
Due to the size of the annuloplasty ring, a 28# ﬂexible band and MC3
ring were more commonly used. There was more 30# rings utilized in
the Flexible Group, and a greater number of 26# bands in the Rigid
Group.Table 3
Inﬂuence of different annuloplasty on TR grade, mPAP and mRVSP.
Variable De Vega group
(n = 242, %)
Flexible band group
(n = 98, %)
Rigid ring group
(n = 59, %)
TRa grade
Preop-a 2.84 ± 1.1 2.70 ± 0.9 2.61 ± 0.7
Postop-a 0.71 ± 0.6b 0.32 ± 0.1b,c 0.20 ± 0.1b,c
mPAPa (mm Hg)
Preop- 34.4 ± 10.3 35.7 ± 11.6 37.1 ± 12.1
Postop- 23.1 ± 9.1b 25.2 ± 9.4b 24.9 ± 10.6b
mRVSPa (mm Hg)
Preop- 43.9 ± 11.0 45.7 ± 12.9 45.1 ± 19.0
Postop- 35.4 ± 13.8 36.3 ± 11.4 35.9 ± 12.7
a TR = tricuspid regurgitation; Preop- = preoperative; Postop- = postoperative;
mPAP = mean pulmonary arterial pressure; mRVSP = mean right ventricular systolic
pressure.
b Comparing with preoperative value: p b 0.01.
c Comparing with De Vega Group: p b 0.05.The operative mortality was 2.3% (9/399). The main cause of death
wasmultiple organ dysfunction syndrome in ﬁve patients. Two patients
died of low output syndrome and the other two died of severe infection.
The cause of death was attributed to pre-operative poor condition
(Table 2).
3.3. Efﬁciency of a different annuloplasty in treating FTR
After surgery, the TR grade andmPAP of all patients signiﬁcantly de-
creased (Table 3). According to the TTE results, at three and six months,
and one and three years during the follow-up, 4.7% (18/383), 8.6%
(33/382), 11.9% (45/378) and 13.7% (51/373) patients were found to
have recurrent TR, respectively. During follow-up, the recurrent rate
of the TR 3+gradewas always higher in the DVGroup than the Flexible
and Rigid Groups. At three years, there were 18.2% of patient graded as
TR 3+ in the DV Group, which was much higher than those in the
Flexible (8.4%, p b 0.05) or Rigid Groups (5.2%, p b 0.05). The recurrent
rates were signiﬁcantly lower in the Rigid Group than in the Flexible
Group at six months, one year, and three years (Fig. 1).
3.4. Risk factors for recurrence TR after tricuspid annuloplasty
Seven patients had a repeat operation to alleviate the recurrent TR.
Four patients underwent TV replacement; in three patients the repair
was successful. One patient died after the repeat operation.
Multivariate analysis revealed that atrial ﬁbrillation, either a preop-
erative 3+ or 4+ grade of TR, LAD ≥ 60 mm, LVEF b 40%, De Vega
annuloplasty, and a postoperative permanent pacemaker installation
were independent risk factors for severe recurrent TR upon tricuspid re-
pair (Table 4).
4. Discussion
Our results showed that though rigid ring annuloplasty did not sig-
niﬁcantly decrease the incidence of adverse clinical outcomes, it was ef-
fective in improving the post-operative TV function in patients with FTR
undergoing mitral surgery. Either the traditional or modiﬁed De Vega
Fig. 1. The recurrent rates of tricuspid regurgitation after three different annuloplasty. *FTR = functional tricuspid regurgitation; Postop- = postoperative.
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Furthermore, a preoperative 3+ or 4+ grade of TR, AF, LAD ≥ 60 mm,
LVEF b 40%, De Vega annuloplasty, and postoperative permanent pace-
maker installationwere independent risk factors for severe recurrent TR
upon tricuspid repair.
The most common etiologies of FTR are right ventricular (RV) dila-
tion and dysfunction from LHD. As in cases of MV disease [23], mild
FTR was reported in up to 74–86% of patients with left heart valve dis-
ease [12]. In our series, 62.9% patients had rheumatic MV pathology,
whichwas similar to previous series [24].MVdisease leads tomitral ste-
nosis, either regurgitation ormix lesion, causing an increase in left atrial
pressure and, in some severe cases, secondary pulmonary hypertension.
Increased afterloadmay lead to RV dysfunction and cardiomyopathy re-
modeling, resulting in either tricuspid annulus dilatation or tethering of
the TV leaﬂets, leading to FTR [1]. By increasing left atrial size and pres-
sure,MVdiseasemight also causeAF,which gradually causes right atrial
enlargement and leads to further tricuspid annular dilation. AF was rec-
ognized as an important risk factor for the development of TR in patients
withMVdisease aswell as for either the occurrence or progression of TR
after MV surgery [1]. Our results show that AF is a primary risk factor of
recurrent moderate to severe TR. Furthermore, patients who had a con-
comitant successful Maze procedure during their MV surgery were re-
ported to have signiﬁcantly less TR at follow-up; however, patients
with AF in our series did not routinely undergo Maze surgery.
FTR is primarily treated with a valve reconstruction that carries a
much lower operative risk than valve replacement [15,25]; however,
there is still a heated debate regarding the superior method of repairTable 4
Risk factors of recurrent tricuspid regurgitation after tricuspid annuloplasty.
Recurrent TR⁎ grade
TR ≤ 2 + (n = 322) TR ≥ 3
Age (year) 45.4 ± 14.7 47.7 ±
Female 175 (54.3%) 26 (50
Atrial ﬁbrillation 119 (27.0%) 49 (96
NYHA⁎ class IV 74 (23.1%) 15 (29
Rheumatic heart disease 221 (68.6%) 30 (58
Mitral stenosis 49 (15.2%) 11 (21
Mitral incompetence 125 (38.8%) 15 (29
Mitral mix lesions 148 (54.0%) 25 (49
LVEF⁎b40% 89 (27.7%) 31 (60
Left atrial diameter ≥ 60 mm 87 (27.0%) 36 (70
mPAP⁎≥50 mm Hg 94 (29.2%) 18 (35
mRVSP⁎≥60 mm Hg 97 (30.1%) 18 (35
Preoperative TR grade ≥ 3+ 207 (64.3%) 47 (92
Tricuspid annulus diameter ≥45 mm 140 (43.5%) 28 (54
Mitral repair 79 (24.5%) 9 (17.6
De Vega annuloplasty 202 (62.7%) 40 (78
Tricuspid prosthetic ring size ≤ 28 mm 102 (29.3%) 7 (13.7
Installation of permanent pacemaker 1 (0.3%) 11 (21
⁎ TR = tricuspid regurgitation; RR = risk ratio; NYHA = New York Heart Association; L
mRVSP = mean right ventricular systolic pressure.(either suture based or a prosthetic ring annuloplasty). McCarthy [26]
reported that both ﬂexible bands and rigid planner rings had much
less recurrent TR than the De Vega procedures. During our follow-up,
it showed the similar results: at three years during follow-up, there
were 18.2% of patient graded as TR 3+ in the DV Group, which was
much higher than those in the Flexible (8.4%) or Rigid Groups (5.2%).
Filsouﬁ [27] and De Bonis [8] found excellent reductions in TR severity
early and mid-term after surgery with the MC3 ring. Ghoreishi [28]
showed that the rigid three-dimensional ring could be themost reliable
and durable treatment for FTR. This ring annuloplasty provides an early
and sustained reduction of TR secondary to LVD, which has been report-
ed by Navia [29]. In our series, the recurrent rates were signiﬁcantly
lower in the Rigid Group than in the Flexible Group postoperatively.
However, though theMC3 ringwas found to be superior to conventional
techniques, about 14% of patients had TR graded greater than moderate
one year after surgery: post-operative TR severity was associated with
preoperative TR severity and extensive leaﬂet tethering [30]. And
Pfannmuller [4] found that though both rigid and ﬂexible systems
could provide acceptable results, but that the use of a rigid ringmay sig-
niﬁcantly increase the risk of early annular dehiscence. These results re-
vealed that all of the annuloplasty methods did not permanently
eliminate secondary TR. Thus, more studies are needed to explore the
superior method of TV repair.
The incidence of a post-operative pacemaker implantation was re-
ported from 3% to 6% after valve interventions [9]. A few studies have
found that the need of pacemakers after a TV operation is higher than
after other valve interventions [2,7,31]; however, the need and clinicalp value Multivariate analysis
+ (n = 51) RR⁎ 95% CI p value
16.4 0.68
.9%) 0.54
.1%) 0.0001 9.4 2.3–65.0 0.001
.5%) 0.43
.8%) 0.043
.6%) 0.31
.4%) 0.16
.0%) 0.09
.1%) 0.001 3.4 1.6–12.1 0.04
.6%) 0.01 2.7 1.2–7.9 0.03
.3%) 0.05
.3%) 0.06
.1%) 0.001 3.6 1.7–8.7 0.002
.9%) 0.04
%) 0.07
.4%) 0.001 7.2 2.7–15.4 0.002
%) 0.32
.5%) 0.02 2.5 1.1–8.7 0.015
VEF = left ventricular ejection fraction; mPAP = mean pulmonary arterial pressure;
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documented. In our series, the rate of pacemaker implantation was 3%
(much lower than other TV operation studies [31,32]) and permanent
pacemaker implantation was found to be an independent risk factor of
recurrent TR during follow-up. One study showed that the survival of
patients who needed a pacemaker after a TV operation was outstand-
ingly higher than of thosewhodid not [31]. More data about the general
results and the need for a pacemaker after the TV operations are essen-
tial for further development of useful methods.
Our study is unique and summarizes the Chinese experience of
treating FTR concomitant with mitral surgery over the past ﬁve years;
however, we realize the potential limitations of our study. First, this is
a retrospective cohort study containing different surgical techniques
that were used in part because of the dissatisfaction with effectiveness,
and surgeon preference. Secondly, the surgical preference may change
in favor of rigid TV annuloplasty over the passage of time. This may
cause some selection bias. Furthermore, a longer follow-up will be
required to conﬁrm our results.
5. Conclusions
Neither traditional normodiﬁed De Vega annuloplasty did not show
a beneﬁcial effect on long-term TV function. Compared with a ﬂexible
system, MC3 rigid ring annuloplasty may provide better effectiveness
in improving postoperative TV function in patientswith FTR undergoing
mitral surgery. Atrial ﬁbrillation, a large left atrium, low LVEF and post-
operative permanent pacemaker installation were independent risk
factors for severe recurrent TR.
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